You are here

Article Text

Article menu
Download PDFPDF
Letter
Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19
  1. Haralampos M Moutsopoulos
  1. Medical Sciences/Immunology, Academy of Athens, Athens, Greece
  1. Correspondence to Professor Haralampos M Moutsopoulos, Medical Sciences/Immunology, Academy of Athens, Athens 115 27, Greece; hmoutsop{at}med.uoa.gr

https://doi.org/10.1136/annrheumdis-2020-217562

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We present a 70-year-old woman who was diagnosed 5 years ago with cryopyrin-associated periodic syndrome on the basis of her clinical picture (episodes of fever, urticarial and maculopapular rash, myalgia, arthralgia and/or arthritis, especially after cold exposure), and genetic testing which confirmed an NLRP3 missense mutation. Since then she has been treated with anti-interleukin-1 subcutaneous therapy (initially on anakinra daily and subsequently on canakinumab 150 mg every 8 weeks). This treatment resulted in complete resolution of disease signs and symptoms. …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.